Zydus Lifesciences Limited
LIC decreased its stake in Zydus Lifesciences from 5.56% to 5.41%, selling 19.37 lakh shares for ₹224.50 Cr at ₹1159.00 apiece.
A vertically integrated pharmaceutical company, Zydus Lifesciences develops, manufactures, and markets generic drugs, specialty pharmaceuticals, and biologics for domestic and international markets. The company operates across multiple therapeutic areas including cardiology, gastroenterology, oncology, and immunology. It serves patients globally through its extensive distribution network, research capabilities, and commitment to addressing unmet healthcare needs across diverse populations and geographies.
India's largest domestic institutional investor with over Rs 56 lakh crore in total AUM, of which roughly Rs 15 lakh crore sits in listed equities. Holds stakes in virtually every major listed Indian company. When LIC builds or exits a position, it moves markets. Government-owned and mandated to invest policyholder funds in Indian equities and bonds, making it the ultimate long-only, long-term India bull.